Story · Medicine & Biotech
David Aggen: Adjuvant Therapy Initiation and Completion Rates Differ Across Phase III Trials
1 outlet · first reported by OncoDaily on
David Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X: “Adjuvant therapy initiation and completion rates differ amongst phase III trials. If you start EV/P neoadjuvant then (OncoDaily)
Coverage, in order
-
David Aggen: Adjuvant Therapy Initiation and Completion Rates Differ Across Phase III TrialsDavid Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X: “Adjuvant therapy initiation and completion rates differ amongst phase III trials. If you start EV/P neoadjuvant then
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.